Life Sciences Edition

RevX Philadelphia

The enterprise AI event for data science and IT leaders

Register now

Experience the magic of RevX alongside AI industry leaders

Moderna logo

About RevX

Explore the future of AI-driven drug development — from discovery through regulatory submissions — with informative sessions on how to improve compliance, collaboration, and efficiency with a modern SCE and flexible AI platform.

Data scientists and IT leaders should attend this one-day, free event for:

Nick Elprin, CEO of Domino

Thought leadership

Hear trends from industry visionaries at top-20 pharma companies.

FINRA

Innovation

Discover AI and data science innovations that power R&D breakthroughs.

Best practice sharing

Learn strategies to take your AI initiatives from proof of concept to real impact.

Networking and connection

Connect with peers to exchange ideas and build valuable relationships.

Speakers

Get ready to be inspired by the voices that are shaping the future of enterprise AI. Stay tuned for exciting updates as we add inspiring customers and thought leaders to our event agenda!

James Black

Executive Director, Technology & Scientific Computing

Novartis

Shahram Ebadollahi

Principal, Nav.AI

Former CDAO, Novartis

Lin Li

Head of Clinical Statistics & Computational Biology

PharmaLex, a Cencora company

Ian Misner, Ph.D.

Head of Products, Oncology Data Science

AstraZeneca

Deepak Bandyopadhyay

Director, Data Science, R&D Quality

Johnson & Johnson

Ronen Artzi, Oncology Data Science and AI, Technology Innovation Lead @ AstraZeneca

Ronen Artzi

Technology Innovation Lead, Oncology Data Science & AI

AstraZeneca

Thomas Robinson

Chief Operating Officer

Domino Data Lab

Chris McSpiritt

VP, Life Sciences Strategy

Domino Data Lab

Matt Tendler

Life Sciences Product Lead

Domino Data Lab

Agenda

  • 8:00 – 9:00a

    Check-in and Breakfast

  • 9:00 – 9:30a

    The Next Chapter: How AI Will Reshape R&D in 2025 and Beyond

    Shahram Ebadollahi Principal, Nav.AI - Former CDAO, Novartis

    Chris McSpiritt VP of Life Sciences Strategy, Domino

    Explore the next chapter of AI in life sciences R&D with Shahram Ebadollahi, former Chief Data Science & AI Officer at Novartis and founder of Nav.AI. Hear about the organizational shifts required to harness AI trends, and what leading companies are doing to stay ahead in 2025, and beyond.
  • 9:30 – 10:00a

    Innovating at Scale: Domino’s Vision for the Future of AI and Data Science

    Thomas Robinson COO, Domino

    Domino COO Thomas Robinson unveils the company’s vision and strategy to help enterprises scale AI and data science with greater speed, governance, and impact. Discover how Domino’s new platform capabilities and AI-native workflows will enhance collaboration and power the next era of innovation.
  • 10:20 – 11:05a

    Principles to Practice: The Role of Policy in Advancing Data Science for Life Sciences R&D

    A former FDA commissioner and leading voice in U.S. health policy explores the evolving role of agencies like the FDA and NIH in advancing FAIR data practices, enabling secure research infrastructure, and guiding the ethical application of AI in drug development and clinical innovation.
  • 11:25 – 12:10p

    From Data to Drug Approval: Bioinformatics in Clinical Development

    Lin Li Head of Clinical Statistics & Computational Biology PharmaLex, a Cencora company

    Bioinformatics and computational biology have powered discovery, but their role in clinical development is evolving. Hear how teams use Domino to scale machine learning and real-word data workflows, accelerating insights and decisions that support drug approval for precision medicine.

    Reimagining Patient Recruitment: How AI and GenAI Are Transforming Clinical Trials

    AI and genAI are streamlining patient recruitment by improving accuracy, reducing trial costs, and accelerating timelines. This company shares how they consolidate data sources, simplify eligibility workflows, and match the right patients to the right trials - faster and with fewer resources.
  • 12:10 – 1:05p

    Networking Lunch

  • 1:05 – 1:50p

    Accelerating Biomarker Discovery with Multi-Agent AI

    Ronen Artzi Technology Innovation Lead, Oncology Data Science & AI, AstraZeneca

    AI-driven, multi-agent systems are transforming cancer biomarker discovery by enabling complex, end-to-end scientific workflows. AstraZeneca shares how they leverage these capabilities to scale insights enhance collaboration, and accelerate decision-making across oncology research.

    Unifying Data Science: A Single SCE for Innovation and Compliance

    James Black Executive Director, Technology & Scientific Computing, Novartis

    Novartis streamlines research and clinical operations by unifying its SCE. Learn how they leverage Domino to improve efficiency, ensure compliance, and balance agility with control, enabling seamless collaboration across data science teams.
  • 2:00 – 2:45p

    Domino for Life Sciences: Product Roadmap

    Matt Tendler Product Lead, Life Sciences, Domino

    Get a first look at Domino’s product roadmap, including upcoming innovations in GenAI development, SCE governance, and automated compliance. Learn how Domino helps teams accelerate discovery, streamline clinical research, and scale data science - all within a GxP-compliant environment.
  • 2:55 – 3:40p

    NLP Suite: A One-Stop Shop for Data-Driven Quality and Compliance

    Deepak Bandyopadhyay Director, Data Science, R&D Quality, Johnson & Johnson

    J&J's NLP Suite unifies diverse text analysis capabilities - including classification, entity harmonization, casual extraction, and trend analytics - into a single, scalable solution. Learn key technical considerations and impacts across clinical operations, pharmacovigilance, and other user groups.

    QC Tracking and Process Governance in the Modern SCE

    Matt Tendler Life Sciences Product Lead, Domino

    Explore challenges and practical solutions for implementing effective QC tracking, managing workflows across roles, and building audit-ready processes without sacrificing agility. Hear best practices to strengthen both compliance and confidence in your SCE.
  • 4:00 – 4:30p

    AI in Drug Discovery: Scaling from Proof of Concept to Real-World Impact

    AI has shown promise in early-stage drug discovery, but moving from proof of concept to real-world impact remains a challenge. In this panel, experts share how they’re deploying AI across oncology and R&D pipelines - navigating data complexity, infrastructure demands, and cross-functional adoption.
  • 4:30 – 5:30p

    Networking Reception

Sponsors

AWS
netapp

Get to know your AI peers and thought leaders

Swipe

On-demand content from RevX 2024